睿知中国医院研究地图
候选清单

邀请入组乳腺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由武汉大学中南医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方武汉大学中南医院Zhongnan Hospital of Wuhan University武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06890871,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:仅女性

    登记记录的入选字段

  2. Pathologically diagnosed as invasive breast cancer; patients with breast cancer confirmed by imaging to have distant metastasis;

    入选标准第 2 条

    HER-2 negative (0/1+/2+ and FISH negative), and the pathological status of ER, PR and PD-L1 has been detected;

    入选标准第 3 条

  3. Has a history of immunodeficiency, including positive HIV test, or has other acquired or congenital immune deficiency diseases, or has a history of organ transplantation and allogeneic bone marrow transplantation, or has active hepatitis (refer to HBV DNA test value over 500 IU/ml or 2500 copies/mL); ⑨ The subject has poorly controlled clinical symptoms or diseases of the cardiovascular system, including but not limited to: (1) NYHA grade II or above heart failure; (2) unstable angina pectoris; (3) having had a myocardial infarction within 1 year; (4) having clinical significance of supraventricular or ventricular arrhythmias that have not been controlled by clinical intervention or still not controlled after clinical intervention;

    排除标准第 16 条

  4. Within 6 months prior to the first administration of the drug, there is a history of gastrointestinal perforation and/or fistula;

    排除标准第 1 条

    Within 4 weeks before the first administration of the study drug, has received any other investigational drug or the time from the last investigational drug administration is no more than 5 half-lives;

    排除标准第 5 条

    Has received anti-tumor treatment (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy or tumor embolization) within 2 weeks before the first administration of the study drug;

    排除标准第 7 条

    Has received PD1/PD-L1 treatment within 6 months;

    排除标准第 12 条

    The toxicity of previous anti-tumor treatment has not recovered to ≤CTCAE 5.0 grade 1 (except for alopecia);

    排除标准第 13 条

  5. ECOG score 0-2; ⑤ ≥ 2 measurable lesions (according to RECIST 1.1.);

    入选标准第 4 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06890871,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥ 18 years old, and willing to participate in this clinical study;
  2. Pathologically diagnosed as invasive breast cancer; patients with breast cancer confirmed by imaging to have distant metastasis;
  3. HER-2 negative (0/1+/2+ and FISH negative), and the pathological status of ER, PR and PD-L1 has been detected;
  4. ECOG score 0-2; ⑤ ≥ 2 measurable lesions (according to RECIST 1.1.);
  5. At least one metastatic lesion that can receive safe radiotherapy (excluding bone metastasis lesions);

排除标准:Exclusion Criteria:

  1. Within 6 months prior to the first administration of the drug, there is a history of gastrointestinal perforation and/or fistula;
  2. There is a history of uncontrollable pleural effusion, pericardial effusion or peritoneal effusion that requires repeated drainage;
  3. There is a history of any allergy to any component of adalimumab;
  4. Has received any of the following treatments:
  5. Within 4 weeks before the first administration of the study drug, has received any other investigational drug or the time from the last investigational drug administration is no more than 5 half-lives;
  6. Has been enrolled in another clinical study at the same time, unless it is an observational (non-interventional) clinical study or a follow-up of an interventional clinical study;
  7. Has received anti-tumor treatment (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy or tumor embolization) within 2 weeks before the first administration of the study drug;
  8. Has received corticosteroids (more than 10mg of prednisone equivalent daily dose) within 2 weeks before the first administration of the study drug. Routine chemotherapy pre-treatment with hormones is allowed without dose adjustment. Other special circumstances need to be communicated with the investigator. In the absence of active autoimmune diseases, inhalation or local use of corticosteroids and doses >10mg/day of prednisone efficacy dose are allowed as an alternative for adrenal cortical hormones;
  9. Has received an anti-tumor vaccine or has received live vaccines within 4 weeks before the first administration of the study drug;
  10. Has undergone major surgery within 6 months or has had severe trauma;
  11. The lesion area has received high-dose radiation therapy;
  12. Has received PD1/PD-L1 treatment within 6 months;
  13. The toxicity of previous anti-tumor treatment has not recovered to ≤CTCAE 5.0 grade 1 (except for alopecia);
  14. Has contraindications to radiotherapy;
  15. Has active autoimmune diseases, autoimmune disease history (such as interstitial pneumonia, colitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to some diseases or syndromes); Excluding vitiligo or cured childhood asthma/allergy, adult patients without any intervention after adulthood; Using stable doses of thyroid replacement hormones for autoimmune-mediated hypothyroidism; Using stable doses of insulin for type I diabetes;
  16. Has a history of immunodeficiency, including positive HIV test, or has other acquired or congenital immune deficiency diseases, or has a history of organ transplantation and allogeneic bone marrow transplantation, or has active hepatitis (refer to HBV DNA test value over 500 IU/ml or 2500 copies/mL); ⑨ The subject has poorly controlled clinical symptoms or diseases of the cardiovascular system, including but not limited to: (1) NYHA grade II or above heart failure; (2) unstable angina pectoris; (3) having had a myocardial infarction within 1 year; (4) having clinical significance of supraventricular or ventricular arrhythmias that have not been controlled by clinical intervention or still not controlled after clinical intervention;

引自 ClinicalTrials.gov, NCT06890871, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06890871,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06890871